Patient-Reported Taxane Neuropathy Foreshadowed Dose Reductions in Black Women With Breast Cancer
Taxane-induced peripheral neuropathy emerged as a clinically decisive toxicity in ECOG-ACRIN EAZ171, where patient-reported symptoms during treatment were tightly linked to chemotherapy dose reduction in Black women with breast cancer. The signal was not subtle: the strongest measure, the FACT-GOG/NTx 4-item subscale, carried an odds ratio of 10.8 for dose reduction, with a 95% confidence interval of 4.5 to 25.9.
This is the kind of toxicity that changes a treatment course in real time. When numbness, tingling, or functional interference begins to accumulate, clinicians often face a narrow set of choices: preserve the planned taxane intensity and risk worsening neuropathy, or reduce the dose and accept the possibility of less chemotherapy exposure.
Prospective Follow-Up Captured Neuropathy, Dose Delivery, and Recovery Patterns
EAZ171 enrolled 249 Black patients scheduled to receive (neo)adjuvant taxane therapy, and 239 participants with patient-reported outcome data formed the analytic cohort. The study design centered on patient experience rather than clinician grading alone, using multiple neuropathy instruments during treatment, including the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity measures, a 4-item subscale, an 11-item subscale, and single-item assessments. Investigators also used PRO-Common Terminology Criteria for Adverse Events numbness/tingling and interference items, allowing symptom burden to be tracked in a way that reflects daily living rather than only exam-room findings.
Two additional measures framed the longer arc of recovery: FACT-G for health-related quality of life and PROMIS Physical Function-10a for physical function, each followed through 12 months. Mixed-effects logistic models then linked neuropathy signals to dose reduction and later declines in patient-reported outcomes.
The statistical pattern was consistent across neuropathy measures. Every patient-reported taxane neuropathy variable associated with dose reduction, but the 4-item FACT-GOG/NTx subscale separated itself from the others with the strongest estimate. In practical terms, the shorter instrument performed best, which matters for future trials and routine care because a brief tool is easier to deploy repeatedly while patients are actively receiving chemotherapy.
Persistent Neuropathy, Not Early Symptoms Alone, Drove Later Functional Harm
Short-term neuropathy during treatment did not translate into reduced quality of life or physical function at 12 months for the cohort as a whole. The 12-month patient-reported outcome dataset was available for 140 patients, representing 59% of the original analytic group. Among those with persistent neuropathy at 12 months, however, the clinical picture changed sharply.
Persistent symptoms were associated with worse HRQOL at 12 months, with an odds ratio of 5.05 and a 95% confidence interval of 1.33 to 19.17. Physical function followed the same direction, with an odds ratio of 5.29 and a 95% confidence interval of 1.57 to 17.83. Those later findings matter because they identify a subgroup for whom neuropathy is not merely an inconvenient toxicity during therapy but a continuing impairment that can affect movement, self-care, and daily activity long after the last infusion.
A brief symptom flare during treatment and a neuropathy syndrome that lingers for a year are not interchangeable clinical states.
Why Patient-Reported Measurement May Be Better at Capturing Taxane Toxicity
Taxanes can injure peripheral nerves through cumulative exposure, and the resulting sensory changes often appear before more obvious functional loss becomes visible in a standard visit. Patient-reported tools are well suited to this toxicity because they capture intensity, frequency, and interference from the patient’s point of view. In this study, those reports aligned closely with treatment modification, suggesting that patients were signaling exactly when taxane tolerance was beginning to fail.
For Black women with breast cancer, the finding carries additional clinical weight. Prior work has shown that Black patients experience higher rates of taxane-induced peripheral neuropathy, and the present analysis places that disparity in a treatment-delivery framework. Neuropathy can prompt dose reduction, and dose reduction can alter the intensity of systemic therapy delivered in the adjuvant or neoadjuvant setting. The pathway from symptom to dose change is therefore not abstract; it is a direct route by which toxicity may influence equity in breast cancer care.
The 4-Item FACT-GOG/NTx Subscale Stood Out as the Most Efficient Tool
Among the neuropathy measures tested, the 4-item FACT-GOG/NTx subscale performed best for predicting dose reduction. That result is especially useful because a shorter patient-reported instrument is more feasible in routine oncology practice, where time pressure and symptom burden often compete for attention. A concise scale that still tracks clinically actionable neuropathy could help teams identify patients before symptoms force a treatment compromise.
The study also suggests a useful distinction between early and persistent neuropathy. Early symptoms were strongly tied to dose reduction, yet they did not predict 12-month functional decline for the cohort as a whole. Persistent neuropathy, by contrast, marked the patients at greatest risk of worse quality of life and worse physical function. In other words, the timing and persistence of neuropathy appear to matter biologically and clinically, likely reflecting whether nerve injury remains reversible or has crossed into longer-lasting dysfunction.
Supportive Care and Equity Depend on Earlier Recognition
These findings support a care model in which patient-reported neuropathy is monitored actively during taxane therapy, not passively collected after toxicity becomes obvious. Early detection can inform dose adjustment, but it can also trigger supportive care, closer follow-up, and counseling about expected symptom trajectories. For patients whose neuropathy persists beyond treatment, continued assessment of function and quality of life should remain part of survivorship care rather than ending with chemotherapy completion.
The data also reinforce the need to design neuropathy assessment tools that are both sensitive and practical. A brief scale that predicts dose modification can be integrated into oncology workflows more readily than a longer instrument, and that efficiency may help close care gaps in populations already experiencing treatment inequity.
The study leaves one important limitation in view: 12-month outcome data were available for only 140 patients, so later recovery patterns remain incompletely characterized. Even so, the central message is firm. In this cohort of Black women with breast cancer, patient-reported taxane neuropathy was not just a symptom inventory; it was a marker of chemotherapy dose reduction and, when persistent, a marker of poorer longer-term quality of life and physical function.